Sonoma Pharmaceuticals (NASDAQ:SNOA) Releases Quarterly Earnings Results, Beats Estimates By $2.33 EPS

Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its quarterly earnings results on Tuesday. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.79) by $2.33, Fidelity Earnings reports. Sonoma Pharmaceuticals had a negative net margin of 62.19% and a negative return on equity of 99.92%. The company had revenue of $4.71 million during the quarter.

Shares of SNOA traded down $0.02 during midday trading on Wednesday, hitting $5.50. 13,335 shares of the stock traded hands, compared to its average volume of 12,902. Sonoma Pharmaceuticals has a 1-year low of $5.30 and a 1-year high of $25.20. The company’s 50 day simple moving average is $6.67.

Separately, ValuEngine raised shares of Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions.

Recommended Story: Hedge Funds – How They Work For Investors

Earnings History for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply